Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423813 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 573
- Enrollment target
NCT00423813 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 573 participants.
The verdict
NCT00423813, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 573 participants
- Enrollment target
Study Summary
The objective of this trial is to evaluate the safety and efficacy of Xyrem® compared to placebo for the treatment of fibromyalgia in a randomized, double blind, placebo controlled, parallel group trial.
Interventions
- DRUG placebo
- DRUG Xyrem®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 573 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00423813
The ClinicalTrials.gov registry entry for NCT00423813 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 573 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00423813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00423813 about?
NCT00423813 is a clinical study titled "A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.". The objective of this trial is to evaluate the safety and efficacy of Xyrem® compared to placebo for the treatment of fibromyalgia in a randomized, double blind, placebo controlled, parallel group trial.
What is the current status of trial NCT00423813?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 573 participants. The study started on 2006-12. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00423813?
The interventions under investigation include: placebo (DRUG), Xyrem® (DRUG).
Who is sponsoring clinical trial NCT00423813?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.